MedTrace Logo

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

NCT06561399 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2024-08-20

No results posted yet for this study

Summary

This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy in patients with Unresectable Hepatocellular Carcinoma (uHCC).

Conditions

  • Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT

TACE, Lenvatinib combination with Sintilimab sequential radiotherapy

TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team

Sponsors & Collaborators

  • Fujian Provincial Hospital

    lead OTHER

Principal Investigators

  • Shao-Ming Wei · Fujian Provincial Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2027-07-01
Completion
2028-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06561399 on ClinicalTrials.gov